EA.hy926 Cells

EA.hy926 cells, are a somatic hybrid cell line widely used in cardiovascular disease research. They are employed in studying various aspects of endothelial cell functions related to angiogenesis, homeostasis/thrombosis, blood pressure regulation, and inflammation.
The cytoplasmic distribution of Weibel-Palade bodies and tissue-specific organelles in EA.hy926 cells, as observed through electron photomicrographs, reflects their differentiated endothelial cell functions. One of the critical advantages of EA.hy926 cells is their ability to undergo more than 100 population doublings (PDLs) while maintaining their cellular properties.
This longevity ensures a sustainable and consistent cell source for long-term experiments and investigations. With a doubling time of 12 hours, these cells exhibit rapid proliferation, facilitating experimental workflows and enabling efficient generation of cell quantities required for large-scale studies.
EA.hy926 cells have proven to be a game-changer in cardiovascular research, particularly in the purification of endothelin converting enzyme (ECE). Traditionally, obtaining primary endothelial cells in significant quantities has been challenging, hindering the sanctification of ECE.
However, EA.hy926 cells, derived from transformed human umbilical vein endothelial cells, have emerged as a reliable alternative for studying ECE activity. This breakthrough has opened up new possibilities for investigating the roles of ECE in cardiovascular diseases and developing potential therapeutic interventions.